Clinical Trial Results: Positive data boosts investor confidence, driving up the stock price. Negative or inconclusive results often lead to a price decline.

Regulatory Approvals: FDA approval of TGTX's therapies significantly increases revenue potential, resulting in a stock price surge. Delays or rejections can have the opposite effect.

Competition: Advances in competing therapies can negatively impact TGTX's market share and stock price. Conversely, setbacks faced by competitors can benefit TGTX.

Market Conditions: Overall market sentiment, particularly towards biotechnology and pharmaceutical stocks, affects TGTX's valuation. Economic downturns can lead to broader market declines.

Financial Performance: Strong revenue growth and profitability generally boost investor confidence. Poor financial performance can lead to selling pressure and a lower stock price.

Partnerships & Acquisitions: Strategic collaborations or acquisitions can increase TGTX's resources and market reach, driving up the stock. Failure to secure partnerships can lead to negative sentiment.

Management Changes: Significant changes in leadership can create uncertainty, potentially impacting the stock price, especially if the new leadership's strategy is unclear.

Analyst Ratings: Positive ratings from financial analysts can attract investors, while negative ratings may discourage them. Changes in analyst target prices also influence stock movements.

Patent Protection: The strength and duration of TGTX's patents protect its therapies from competition. Patent disputes or expirations can negatively affect the stock price.